You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Through Primary Focus Targeted Protein Degradation (TPD), Astellas is committed to accelerating the delivery of safe and effective protein degradation therapies for the targeted treatment of cancer and other diseases with high unmet medical needs.
Protein degradation has the potential to reshape expectations for what is possible for treating many types of diseases by unlocking and degrading disease relevant proteins that have previously been considered ‘undruggable’. This is due to the unique ability of protein degraders to harness the body’s natural protein disposal system and their ability to bind via ternary complexes to disease-related proteins in a way that traditional small molecule inhibitors cannot.
At Astellas, we believe the TPD modality could potentially transform the treatment landscape for some of the world’s most devastating diseases. As one of our Primary Focuses, we are making strategic investments in TPD to accelerate our research and development, bringing together the right expertise and capabilities to realize the platform’s therapeutic potential.
The advantages of protein degraders, in addition to their ability to access undruggable targets, include their permeability (they may be able to penetrate the cell membrane and blood brain barrier), and their high levels of specificity to the target. Alongside our innovative partners, we are committed to making a meaningful impact and delivering significant VALUE through this exciting new potential therapeutic approach.
Astellas has the following TPD capabilities:
Our Flagship program within Primary Focus Targeted Protein Degradation is ASP3082, a novel protein degrader, originally discovered by Astellas, that targets mutated KRAS G12D protein. It is currently in Phase 1 clinical trials for the treatment of solid tumors harboring the KRAS G12D mutation, having demonstrated superior anti-tumor effect in preclinical studies when compared to conventional small molecule inhibitors. If successfully tested in clinical studies and approved, ASP3082 could become a first-in-class therapy as a protein degrader and could potentially reshape the treatment paradigm for cancer patients with KRAS G12D mutations.
The rapid progress of ASP3082 illustrates Astellas’ dedication, ingenuity and capabilities in TPD. We achieved this by drawing on our deep heritage and experience in oncology, our proprietary KRAS research, our artificial intelligence and robotics capabilities, and our expertise in successfully developing targeted medicines – all of which we are applying to our current pipeline.
Please view our pipeline for Targeted Protein Degradation below. You can also access the full Astellas pipeline page here.
To advance this complex, next-generation modality in oncology and beyond, we seek to combine our in-house expertise with like-minded, ambitious innovators in the field. Specifically, we are pursuing strategic partnerships that complement our efforts to harness new protein of interest and E3 ligase binders, enhance our understanding of challenges such as cell resistance and tumor recurrence, advance next generation induced-proximity technologies and help establish the infrastructure needed to expedite the development and delivery of these novel therapies to patients.
To learn more about how to collaborate with Astellas, please visit our Partnering page.
Astellas strives to match the best science and the best talent in order to deliver on our mission to turn innovative science into VALUE for patients. We encourage you to visit our Careers page to learn how you can join our work to turn innovative science into VALUE for patients.
